JP2013527173A5 - - Google Patents

Download PDF

Info

Publication number
JP2013527173A5
JP2013527173A5 JP2013509262A JP2013509262A JP2013527173A5 JP 2013527173 A5 JP2013527173 A5 JP 2013527173A5 JP 2013509262 A JP2013509262 A JP 2013509262A JP 2013509262 A JP2013509262 A JP 2013509262A JP 2013527173 A5 JP2013527173 A5 JP 2013527173A5
Authority
JP
Japan
Prior art keywords
methyl
pyridinyl
oxo
dihydro
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013509262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013527173A (ja
JP5889875B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/035344 external-priority patent/WO2012005805A1/en
Publication of JP2013527173A publication Critical patent/JP2013527173A/ja
Publication of JP2013527173A5 publication Critical patent/JP2013527173A5/ja
Application granted granted Critical
Publication of JP5889875B2 publication Critical patent/JP5889875B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013509262A 2010-05-07 2011-05-05 アザインダゾール Expired - Fee Related JP5889875B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33231410P 2010-05-07 2010-05-07
US61/332,314 2010-05-07
PCT/US2011/035344 WO2012005805A1 (en) 2010-05-07 2011-05-05 Azaindazoles

Publications (3)

Publication Number Publication Date
JP2013527173A JP2013527173A (ja) 2013-06-27
JP2013527173A5 true JP2013527173A5 (enExample) 2014-06-26
JP5889875B2 JP5889875B2 (ja) 2016-03-22

Family

ID=45441481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013509262A Expired - Fee Related JP5889875B2 (ja) 2010-05-07 2011-05-05 アザインダゾール

Country Status (5)

Country Link
US (1) US8637509B2 (enExample)
EP (1) EP2566479B1 (enExample)
JP (1) JP5889875B2 (enExample)
ES (1) ES2528269T3 (enExample)
WO (1) WO2012005805A1 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
US8536179B2 (en) 2010-05-07 2013-09-17 Glaxosmithkline Llc Indoles
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3363B1 (ar) * 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
AU2013203641B2 (en) * 2011-04-13 2014-08-21 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
US9073924B2 (en) * 2011-09-13 2015-07-07 Glaxosmithkline Llc Azaindazoles
CA2854447A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
HUE042271T2 (hu) 2012-03-12 2019-06-28 Epizyme Inc Emberi EZH2 inhibitorai és azok alkalmazási eljárásai
EP2828250B1 (en) 2012-03-19 2021-03-10 Imperial College Innovations Limited Quinazoline compounds and their use in therapy
DK3628670T3 (da) 2012-04-13 2022-12-05 Epizyme Inc Saltform til ezh2-hæmning
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
EP3970725B1 (en) 2012-09-07 2025-08-20 Massachusetts Eye & Ear Infirmary A gamma secretase inhibitor for treating hearing loss
US20150239842A1 (en) * 2012-09-28 2015-08-27 Pfizer Inc. Benzamide and heterobenzamide compounds
CN105102432B (zh) 2012-10-15 2019-01-04 Epizyme股份有限公司 经取代的苯化合物
KR102021642B1 (ko) 2012-10-15 2019-09-16 에피자임, 인코포레이티드 암을 치료하는 방법
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
AU2013361079B2 (en) 2012-12-21 2018-07-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム,インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970136A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
EP2970131B1 (en) 2013-03-14 2017-11-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
WO2014153226A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970181B1 (en) 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
KR20150127216A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 암의 치료 및 암 약물 내성의 예방 방법
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9505745B2 (en) 2013-04-30 2016-11-29 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
EP3019494B1 (en) 2013-07-10 2017-06-21 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
US9624205B2 (en) * 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EP3057962B1 (en) 2013-10-16 2023-10-18 Epizyme, Inc. Hydrochloride salt form for ezh2 inhibition
US10603295B2 (en) 2014-04-28 2020-03-31 Massachusetts Eye And Ear Infirmary Sensorineural hair cell differentiation
CN105017221B (zh) * 2014-04-30 2019-05-28 中国医学科学院药物研究所 苯并咪唑衍生物及其制法和药物组合物与用途
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
JP2017533922A (ja) * 2014-11-06 2017-11-16 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 移植片対宿主病(gvhd)のためのクロマチン構造を調節する組成物の使用
WO2016073956A1 (en) * 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ezh2抑制劑
WO2016102493A1 (en) * 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
EP3236962A2 (en) 2014-12-23 2017-11-01 University of Copenhagen Treatment of cancer by inhibiting ezh2 activity
US10961532B2 (en) 2015-04-07 2021-03-30 The General Hospital Corporation Methods for reactivating genes on the inactive X chromosome
JP2018522045A (ja) * 2015-08-03 2018-08-09 コンステレーション・ファーマシューティカルズ・インコーポレイテッドConstellation Pharmaceuticals,Inc. Ezh2阻害剤および制御性t細胞機能の調節
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
WO2017084494A1 (zh) * 2015-11-19 2017-05-26 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CA3013038A1 (en) 2016-01-29 2017-08-03 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
AU2017217688B2 (en) 2016-02-10 2023-01-19 Wake Forest University Health Sciences Model system of liver fibrosis and method of making and using the same
EP3445365A4 (en) 2016-04-22 2019-10-16 Dana-Farber Cancer Institute, Inc. EZH2 INHIBITORS AND USES THEREOF
WO2017192290A1 (en) 2016-05-04 2017-11-09 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and platinum-based antineoplastic drugs
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
MY198008A (en) 2017-05-18 2023-07-25 Jiangsu Hengrui Medicine Co Crystal of benzofuran derivative free base and preparation method
BR112020008325A2 (pt) 2017-11-14 2020-10-20 Pfizer Inc. terapias de combinação com o inibidor de ezh2
JP2021531340A (ja) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのprc2サブユニットの阻害
JP2022510501A (ja) 2018-10-30 2022-01-26 リペア セラピューティクス インコーポレイテッド 化合物、医薬組成物、ならびに化合物の調製方法及びatrキナーゼ阻害剤としてのその使用方法
WO2020192650A1 (zh) 2019-03-25 2020-10-01 上海华汇拓医药科技有限公司 酰胺类化合物制备方法及其在医药领域的应用
WO2020216898A1 (en) 2019-04-24 2020-10-29 Institut Curie Biomarkers for predicting resistance to cancer drugs
AU2020317381A1 (en) * 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
US12110294B2 (en) * 2020-05-01 2024-10-08 Gilead Sciences, Inc. CD73 compounds
WO2022068929A1 (zh) * 2020-09-30 2022-04-07 武汉人福创新药物研发中心有限公司 嘧啶二酮类化合物及其用途
CN113292489B (zh) * 2021-06-16 2022-08-30 泓博智源(开原)药业有限公司 二氯代二烷基烟腈的制备方法
AU2022376954B2 (en) 2021-10-29 2026-04-23 Gilead Sciences, Inc. Cd73 compounds
AU2023292893A1 (en) 2022-06-13 2025-01-02 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
JP2025525324A (ja) 2022-06-13 2025-08-05 ツリーライン バイオサイエンシズ インコーポレイテッド 1,8-ナフチリジン-2-オンヘテロ二官能性bcl6分解剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2651072A1 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2009006577A2 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
EP2285783B1 (en) * 2008-04-29 2014-05-21 Boehringer Ingelheim International GmbH Indazole compounds as ccr1 receptor antagonists
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds

Similar Documents

Publication Publication Date Title
JP2013528591A5 (enExample)
JP2013544840A5 (enExample)
JP2013525498A5 (enExample)
CA2798622A1 (en) Indoles
AU2006200437B2 (en) Substituted alkylamine derivatives and methods of use
AU2016358242B2 (en) N-substituted indole derivatives as PGE2 receptor modulators
AU2003252011B2 (en) Substituted 2-alkylamine nicotinic amide derivatives and use there of
EA016028B1 (ru) Конденсированные гетероциклические производные и их применение
JP2018118992A5 (enExample)
AU2018201953A1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
TW200413330A (en) Compounds for the treatment of abnormal cell growth
BR112020003254A2 (pt) moduladores da piruvato quinase e uso destes
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
HRP20180546T1 (hr) Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti
JP2015508828A5 (enExample)
ME02416B (me) Trpv4 antagonisтi
JP2016500073A5 (enExample)
AU2002248340A1 (en) Substituted alkylamine derivatives and methods of use
JP2020526556A5 (enExample)
BRPI0721137A2 (pt) Compostos para modulação de atividade de c-fms e/ou c-kit e usos para os mesmos.
AU2007271964A1 (en) Pyrimidine derivatives as ALK-5 inhibitors
JP2015501784A5 (enExample)
JP2013515736A (ja) キナーゼ調節のための化合物及び方法ならびにそれらの適応症
US20250179013A1 (en) Inhibitors of rna helicase dhx9 and uses thereof
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета